PAVE Latin America
Latest news

22nd March 2024, the Yanomami Indigenous people, in Roraima, became the first in Brazil to receive tafenoquine and point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing for P. vivax malaria, following the decision of the government to adopt the use of these new health technology innovations.

On 4th March 2024, The Lancet Infectious Diseases published operational real-world effectiveness data confirming the public health and patient benefits of using quantitative G6PD testing and tafenoquine in P. vivax malaria case management in Brazil.

The Tafenoquine Roll-out STudy (TRuST) in the Brazilian Amazon, published in Lancet Global Health, demonstrates the operational feasibility of introducing single-dose tafenoquine alongside quantitative G6PD testing for Plasmodium vivax radical cure.

Medicines for Malaria Venture (MMV) and PATH are excited to announce that Brazil has become the first malaria-endemic country to incorporate the STANDARD trade; G6PD Test and single-dose tafenoquine in the public health system for the treatment of P. vivax malaria.

A celebratory event hosted by Brazil's Minister of Public Health and PAVE to mark the first-ever adoption of G6PD testing and tafenoquine usage for P. vivax malaria in the Brazilian SUS

The Ministry of Health Peru (MINSA) hosted a World Malaria Day event, inviting the Partnership for Vivax Elimination (PAVE) team to present the actions executed and ongoing in Latin America, and new tools to combat Plasmodium vivax malaria. The event was broadcast in Spanish and was live streamed on Youtube.

On November 8, 2022, PAVE will host its 3rd Regional Meeting with stakeholders involved in the fight against P. vivax malaria in the Americas.

The Partnership for Vivax Elimination (PAVE) organized the second annual Regional Meeting for Latin America, bringing together National Malaria Control Programs from Brazil, Peru and Colombia, along with regional and global organizations involved in the fight against P. vivax malaria in the region.

GORCoP Webinar: The validation and operational use of point-of-care G6PD testing in the Brazilian Amazon.